# US 2017/0319538 A1 · Solid pharmaceutical compositions containing benzofuran derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0319538 A1
- Document ID: US20170319538A1
- Status: Published application
- Kind: A1
- Application number: 15/660,133
- Filed: 2017-07-26
- Published: 2017-11-09
- Earliest claimed: 1997-06-23
- Assignees: Sanofi
- Applicants: Sanofi
- Inventors: Bernard ABRAMOVICI; Jean-Claude GAUTIER; Jean-Claude GROMENIL; Jean-Marie MARRIER
- Web page: https://patentgrep.com/patent/US20170319538A1

## CPC

- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/06: Antiarrhythmics
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to a solid pharmaceutical composition for oral administration characterized in that it comprises a benzofuran derivative with antiarrhythmic activity, or one of the pharmaceutically acceptable salts thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients.

## Claims

### Claim 1

A solid pharmaceutical composition for oral administration comprising dronedarone, or a pharmaceutically acceptable salt thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients, wherein said pharmaceutical composition has a pharmacokinetic profile wherein the maximum plasmatic concentration of active principle following a single oral administration in a non-fasted human is less than about five times the maximum concentration of active principle following a single oral administration in a fasted human.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the active principle is dronedarone hydrochloride.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the nonionic hydrophilic surfactant is selected from the group consisting of poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338, poloxamer 407, and polyethylene hydroxystearate 660.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the nonionic hydrophilic surfactant is poloxamer 407.

### Claim 5 (depends on 1)

The pharmaceutical composition according to claim 1, which is in a tablet or a gelatin capsule form, wherein the nonionic hydrophilic surfactant is present in a proportion of from 1% to 50% by weight of the active principle in base form.

### Claim 6

A solid pharmaceutical composition for oral administration comprising dronedarone, or a pharmaceutically acceptable salt thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients, wherein said pharmaceutical composition exhibits a mean AUC of the active principle following a single oral administration in a non-fasted human which is less than about five times the mean AUC of the active principle following a single oral administration of the pharmaceutical composition in a fasted human.

### Claim 7 (depends on 6)

The pharmaceutical composition according to claim 6, wherein the active principle is dronedarone hydrochloride.

### Claim 8 (depends on 6)

The pharmaceutical composition according to claim 6, wherein the nonionic hydrophilic surfactant is selected from the group consisting of poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338, poloxamer 407, and polyethylene hydroxystearate 660.

### Claim 9 (depends on 6)

The pharmaceutical composition according to claim 6, wherein the nonionic hydrophilic surfactant is poloxamer 407.

### Claim 10 (depends on 6)

The pharmaceutical composition according to claim 6, which is in a tablet or a gelatin capsule form, wherein the nonionic hydrophilic surfactant is present in a proportion of from 1% to 50% by weight of the active principle in base form.

### Claim 11

A solid pharmaceutical composition for oral administration comprising 200 to 400 mg of dronedarone hydrochloride, calculated in base form, and poloxamer 407, optionally in combination with one or more pharmaceutical excipients.

### Claim 12

A method of treating a patient comprising orally administering a solid pharmaceutical composition comprising dronedarone, or a pharmaceutically acceptable salt thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients, wherein the bioavailability of the composition following a single oral administration in the not fasted state is less than about five times the bioavailability of the composition following a single oral administration in the fasted state.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the active principle is dronedarone hydrochloride.
